Gene Biotherapeutics is pioneering “medical revascularization,” a fundamentally new and novel, DNA-based therapeutic platform, based on a mechanism of action that increases blood flow to ischemic tissues by stimulating arteriogenesis (enlargement of existing arterioles) and angiogenesis (formation of new capillary vessels).
Our technology platform utilizes FGF-4, a key angiogenic growth factor, in concert with an adenovirus gene delivery system that, based on a single treatment, is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral and other medical conditions and diseases, as well as for advanced tissue engineering applications. A central finding from the Generx clinical development program is that cardiac ischemia drives Generx transfection into heart cells, and that regional cardiac ischemia is an essential precursor to support the growth of collateral blood vessels for treatment response to Generx angiogenic gene therapy.
